Welcome to our dedicated page for Eupraxia Pharmaceuticals news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmaceuticals stock.
Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced on May 1, 2026 the appointment of Dr. Jeymi Tambiah as Chief Medical Officer and the retirement of Dr. Mark Kowalski, who will support the company as a senior consultant during transition.
Dr. Tambiah brings over 18 years of clinical development, regulatory and commercialization experience and will support late‑stage development of EP‑104GI in eosinophilic esophagitis and expansion of the gastroenterology pipeline using the Diffusphere™ platform.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) will present four abstracts at Digestive Disease Week (May 2-5, 2026) in Chicago, including an oral presentation May 3 and three posters May 5 reporting clinical data from the Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE).
The company will host a virtual investor event May 4 at 7am CT featuring KOLs discussing recurrent esophageal strictures and EP-104GI’s potential to prevent strictures; materials will be posted on Eupraxia’s website after presentations.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported 36-week tissue health and symptom results for the highest dose cohort (Cohort 9) in its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis.
Cohort 9 (n=3) showed a 90% EoEHSS Stage reduction, 88% Grade reduction, 72% PEC reduction, and 66% clinical remission maintained from week 8 through week 36. No drug-related SAEs or cases of oropharyngeal candidiasis were reported across 31 patients and >230 patient-months.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced management will present at two investor conferences in April 2026: Raymond James Biotech Innovation Symposium (1x1 meetings) on April 14, 2026 in New York, and Bloom Burton & Co. Healthcare Investor Conference (presentation and 1x1 meetings) on April 21-22, 2026 in Toronto.
The company will present on April 21 at 11:00 AM ET and provide a webcast for investors at the listed link.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported 24-week symptom data from the highest dose cohort in the Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis. Cohort 9 (n=3) showed a mean SDI reduction of 4.0 points at 24 weeks (3 points = clinical remission).
Pooled cohorts 4-9 showed clinical remission in 59% at 12 weeks (13/22), 76% at 24 weeks (13/17), and 67% at 52 weeks (6/9). No SAEs reported across 31 patients and >220 patient-months; no oropharyngeal candidiasis observed.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q4 2025 results, highlighted by clinical progress in its lead program EP-104GI and strengthened liquidity from a Feb 20, 2026 public offering.
Key figures: net loss $16.7M for Q4 2025, cash $80.5M at Dec 31, 2025, and an offering that raised approximately $63.2M. Management expects funding into the second half of 2028.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced the closing of a public offering on Feb 20, 2026 raising approximately US$63.2 million gross from 7,607,145 common shares and pre-funded warrants, including full exercise of the underwriter option. Proceeds will fund EP-104GI clinical development, manufacturing, R&D and corporate purposes.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) priced a public offering on Feb 19, 2026 to raise approximately US$55 million through 6,428,574 common shares at US$7.00 and pre-funded warrants for up to 1,428,571 shares at US$6.99999 each.
The Offering includes a 30-day underwriter option for an additional 1,178,571 common shares and is expected to close on Feb 20, 2026, subject to TSX and Nasdaq listing approvals. Proceeds are earmarked primarily to advance EP-104GI clinical programs, expand indications, R&D, business development and general corporate purposes.
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) filed a preliminary prospectus supplement on Feb 18, 2026 for a proposed public offering of common shares (or pre-funded warrants) and may grant underwriters a 30-day option for up to an additional 15% of the offering.
The company intends to use net proceeds primarily to advance EP-104GI through preclinical work, Phase 2 and Phase 3 preparations, manufacturing, and commercial readiness, plus additional GI indications, R&D, business development, IP expansion and general corporate purposes. Closing is subject to customary conditions and required TSX and Nasdaq approvals.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive tissue health and symptom data from the ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis. At 12 weeks the highest-dose cohort (8mg/site, 20 sites, n=3) showed near-complete tissue normalization (EoEHSS Grade -0.57 [94%], Stage -0.63 [97%]). Patients in 4mg/site cohorts (n=9) maintained 12-week improvements at 36 weeks (Grade -0.22, Stage -0.24). Among patients with ≥60% esophagus treated, clinical remission was 58% at 12 weeks (n=19), 79% at 24 weeks (n=14), and 67% at 52 weeks (n=6). Safety: >200 patient-months in 31 patients with no SAEs and no oral candidiasis reported.